DaVita (NYSE:DVA) Shares Down 3.9% – What’s Next?

DaVita Inc. (NYSE:DVA) shares fell 3.9% during trading on Tuesday. The company traded as low as $187.91 and last traded at $179.6140. 103,555 shares traded hands during trading, a decline of 88% from the average daily volume of 882,677 shares. The stock had previously closed at $187.00.

Analysts Set New Price Targets

Several research firms have weighed in on DVA. TD Cowen reiterated a “buy” rating on shares of DaVita in a research note on Wednesday. Truist Financial dropped their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. UBS Group increased their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Finally, Raymond James Financial set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.43.

DaVita Price Performance

The stock has a fifty day simple moving average of $180.38 and a 200-day simple moving average of $191.46. The company has a market capitalization of $11.27 billion, a price-to-earnings ratio of 14.46, a P/E/G ratio of 0.45 and a beta of 0.80.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Institutional Trading of DaVita

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its holdings in DaVita by 831.4% in the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after buying an additional 34,287 shares during the last quarter. Berkshire Hathaway Inc acquired a new position in shares of DaVita during the second quarter valued at approximately $6,425,269,000. Wellington Management Group LLP raised its holdings in shares of DaVita by 305.1% during the second quarter. Wellington Management Group LLP now owns 9,610 shares of the company’s stock valued at $2,138,000 after acquiring an additional 7,238 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of DaVita by 30.5% in the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after acquiring an additional 10,477 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of DaVita by 27.4% in the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.